Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Manager, CE Supporter Outreach
Ms. Moonan has disclosed the following relationship with commercial interests: AstraZeneca: Stockholder/Former Employee.
Ann Gianola, MA, Manager, Medical Education Accreditation and Grant Development
Ms. Gianola has disclosed the following relationship with commercial interests: Actelion: Grant/Research Support.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Sun D, Tainsky MA, Haddad R. Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy. Transl Oncologenomics 2012;5:1–7.
Bottillo I, Ahlquist T, Brekke H et al.. Germline and somatic NF1 mutations in sporadic and NF-1 associated malignant nerve sheath tumors. J Pathol 2009;217:693–701.
Jessen WJ, Miller SJ, Jousma E et al.. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013;123:340–347.
Ambrosini G, Cheema HS, Seetman S et al.. Sorafenib inhibits growth and MAPK signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2012;7:890–896.
Whittaker S, Kirk R, Hayward R et al.. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2010;2:35ra41.
Maki RG, D’Adamo DR, Keohan ML et al.. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133–3140.
Serrano C, Simonetti S, Hernandez-Losa J et al.. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumors. Histopathology 2013;62:499–504.
Serrano C, Simonetti S, Hernandez J et al.. BRAF V600E mutations in benign and malignant nerve sheath tumors [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 10043.
Schindler G, Capper D, Meyer J et al.. Analysis of BRAF v600e mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma, and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405.
Kumar R, Angelini S, Snellman E et al.. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342–348.
Kopetz S, Desai J, Chan E et al.. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract 3534.
Chapman PB, Hauschild HA, Haanen RC et al.. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.
Koivunen JP, Mermel C, Zejnullah K et al.. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275–4283.
Nazarian R, Shi H, Wang Q et al.. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973–977.
Trunzer K, Pavlick AC, Schuchter L et al.. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767–1774.
Flaherty KT, Jeffrey R, Infante JR et al.. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–1703.
Prahallad A, Sun C, Huang S et al.. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:101–104.
Mao M, Tian F, Mariadason JM et al.. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19:657–667.
Montero-Conde C, Ruiz-Llorente S, Dominguez JM et al.. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013;3:520–533.
DeClue JE, Heffelfinger S, Benvenuto G et al.. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:1233–1241.
Zou CY, Smith KD, Zhu QS et al.. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 2009;8:1157–1168.
Poulikakos PI, Persaud Y, Janakiraman MJ et al.. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480:387–390.